Details

Autor(en) / Beteiligte

• Gerotziafas, Grigoris T
• Catalano, Mariella
• Colgan, Mary-Paula
• Pecsvarady, Zsolt
• Wautrecht, Jean Claude
• Fazeli, Bahare
• Olinic, Dan-Mircea
• Farkas, Katalin
• Elalamy, Ismail
• Falanga, Anna
• Fareed, Jawed
• Papageorgiou, Chryssa
• Arellano, Rosella S
• Agathagelou, Petros
• Antic, Darco
• Auad, Luciana
• Banfic, Ljiljana
• Bartolomew, John R
• Benczur, Bela
• Bernardo, Melissa B
• Boccardo, Francesco
• Cifkova, Renate
• Cosmi, Benilde
• De Marchi, Sergio
• Dimakakos, Evangelos
• Dimopoulos, Meletios A
• Dimitrov, Gabriel
• Durand-Zaleski, Isabelle
• Edmonds, Michael
• El Nazar, Essam Abo
• Erer, Dilek
• Esponda, Omar L
• Gresele, Paolo
• Gschwandtner, Michael
• Gu, Yongquan
• Heinzmann, Mónica
• Hamburg, Naomi M
• Hamadé, Amer
• Jatoi, Noor-Ahmed
• Karahan, Oguz
• Karetova, Debora
• Karplus, Thomas
• Klein-Weigel, Peter
• Kolossvary, Endre
• Kozak, Matija
• Lefkou, Eleftheria
• Lessiani, Gianfranco
• Liew, Aaron
• Marcoccia, Antonella
• Marshang, Peter
• Marakomichelakis, George
• Matuska, Jiri
• Moraglia, Luc
• Pillon, Sergio
• Poredos, Pavel
• Prior, Manlio
• Salvador, David Raymund K
• Schlager, Oliver
• Schernthaner, Gerit
• Sieron, Alexander
• Spaak, Jonas
• Spyropoulos, Alex
• Sprynger, Muriel
• Suput, Dusan
• Stanek, Agata
• Stvrtinova, Viera
• Szuba, Andrzej
• Tafur, Alfonso
• Vandreden, Patrick
• Vardas, Panagiotis E
• Vasic, Dragan
• Vikkula, Miikka
• Wennberg, Paul
• Zhai, Zhenguo

Titel

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Ist Teil von

• Thrombosis and haemostasis, 2020-12, Vol.120 (12), p.1597

Ort / Verlag

Germany

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.